NRC 2694A
Alternative Names: NRC-2694; NRC-2694-ALatest Information Update: 04 Oct 2022
Price :
$50 *
At a glance
- Originator Natco Pharma
- Class Antineoplastics; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Squamous cell cancer
- No development reported Breast cancer; Solid tumours
Most Recent Events
- 30 Sep 2022 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Recurrent, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT05283226)
- 27 Jul 2022 NRC 2694A is still in phase II trials for Squamous cell cancer in India (CTRI/2019/06/019649)
- 25 Sep 2019 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Late-stage disease) in India (PO) (CTRI/2019/06/019649)